TABLE 4.
ECESBL-1: phenotypic susceptibility and resistance gene annotation in MinION and whole-genome MiSeq assemblies
| Gene identified |
Targeted drug class | Antibiotic | MIC (μg/ml) or zone | Interpretationa | |
|---|---|---|---|---|---|
| MinION | Whole-genome SPAdes | ||||
| blaTEM-1B | blaTEM-1B | Penicillins | Ampicillin | >16 | R |
| blaCMY-42 | blaCMY-42 | Cephalosporins/cephamycins | Cefazolin | >4 | R |
| blaCTX-M-24 | Cefoxitin | >16 | R | ||
| Cefotaxime | >64 | R | |||
| Ceftriaxone | >32 | R | |||
| Ceftazidime | >128 | R | |||
| Cefepime | >16 | R | |||
| Monobactams | Aztreonam | >16 | R | ||
| Beta-lactams/beta-lactamase inhibitors | Amoxicillin-clavulanic acid | >16 | R | ||
| Piperacillin-tazobactam | 32 | I | |||
| strA | strA | Aminoglycosides | Amikacin | ≤8 | S |
| strB | strB | Gentamicin | >8 | R | |
| aac(3)-IId | aac(3)-IId | Tobramycin | ≤4 | S | |
| aadA5 | aadA5 | ||||
| sul1 | sul1 | Sulfonamides | Trimethoprim-sulfamethoxazole | >2 | R |
| sul2 | sul2 | ||||
| dfrA17 | dfrA17 | ||||
| tet(B) | tet(B) | Tetracyclines | Tetracycline | No zone | R |
| Doxycycline | No zone | R | |||
| erm(B) | mph(A) | Macrolides | Azithromycin | No zone | No CLSI interpretation |
| mph(A) | |||||
| None identified | None identified | Fluoroquinolones | Ciprofloxacin | >2 | R |
| Levofloxacin | >4 | R | |||
| None identified | None identified | Carbapenems | Doripenem | ≤1 | S |
| Ertapenem | ≤0.5 | S | |||
| Imipenem | ≤1 | S | |||
| Meropenem | ≤1 | S | |||
a
R, resistant; I, intermediate; S, susceptible.